Sai Parenterals Limited (SAIPARENT)
₹487.30 +0.70% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Sai Parenterals' revenue was ₹179 Cr (+435.1% year on year, -9.8% on the previous quarter), and net profit ₹7.9 Cr (+458.0% year on year); the operating margin was 13.2%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹179 | +435.1% | -9.8% |
| Operating profit | ₹23.5 | +396.2% | -9.5% |
| Net profit | ₹7.9 | +458.0% | -39.1% |
| EPS (₹) | 1.79 | +244.2% | -39.9% |
| Operating margin | 13.2% | — | — |
SAIPARENT delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 55.12% of the SAIPARENT shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.34%. That is close to its usual level.
Delivery in the last 5 sessions: 55.3% · 53.8% · 46.5% · 59.5% · 55.1%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sai Parenterals has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited for Rs 15 crore, funded from unutilised IPO proceeds. The acquisition replaces an originally planned greenfield R&D centre at Genome Valley, Hyderabad, adding 28 research scientists and an active pipeline of 150 SKUs across 86 molecules. Prathyak has been renamed Sai Prathyak Laboratories Private Limited and becomes a direct subsidiary. Sai Parenterals also holds a Right of First Refusal (ROFR) to acquire the remaining 40% at the same valuation using internal accruals.
- Acquired 60% stake in Prathyak Laboratories for Rs 15 crore, valuing the entity at Rs 25 crore
- Funded via unutilised net proceeds from the company's recent initial public offering
- Adds an operating R&D facility with 28 research scientists and 150 SKUs across 86 molecules
- Includes Right of First Refusal (ROFR) to acquire the remaining 40% stake at the same valuation
- Replaces planned greenfield R&D construction, avoiding setup delays
Sai Parenterals Limited announced key leadership appointments approved at its board meeting on September 30, 2026. The company appointed Mr. Arvind Gannimitta, who holds a Ph.D. and brings over 26 years of pharmaceutical operations experience, as Chief Operating Officer (COO). Additionally, Mr. Ashwani Singh Bisht was appointed as Company Secretary and Compliance Officer (KMP) following the resignation of Ms. Shivali Aggarwal effective September 30, 2026. The COO appointment strengthens operations oversight as the company navigates recent quarterly revenue of Rs 178.67 Cr (Jun 2026).
- Appointment of Mr. Arvind Gannimitta (Ph.D.) as Chief Operating Officer effective September 30, 2026, bringing over 26 years of pharmaceutical operations experience.
- Appointment of Mr. Ashwani Singh Bisht (Membership No. A72076) with over 12 years of professional experience as CS and Compliance Officer.
- Resignation of Ms. Shivali Aggarwal as CS and Compliance Officer finalized effective September 30, 2026, due to personal reasons.
- Board meeting commenced at 10:30 a.m. and concluded at 11:45 a.m. on September 30, 2026.
Sai Parenterals Limited announced key leadership appointments approved at its board meeting on September 30, 2026. The company appointed Mr. Arvind Gannimitta, who holds a Ph.D. and brings over 26 years of pharmaceutical operations experience, as Chief Operating Officer (COO). Additionally, Mr. Ashwani Singh Bisht was appointed as Company Secretary and Compliance Officer (KMP) following the resignation of Ms. Shivali Aggarwal effective September 30, 2026. The COO appointment strengthens operations oversight as the company navigates recent quarterly revenue of Rs 178.67 Cr (Jun 2026).
- Appointment of Mr. Arvind Gannimitta (Ph.D.) as Chief Operating Officer effective September 30, 2026, bringing over 26 years of pharmaceutical operations experience.
- Appointment of Mr. Ashwani Singh Bisht (Membership No. A72076) with over 12 years of professional experience as CS and Compliance Officer.
- Resignation of Ms. Shivali Aggarwal as CS and Compliance Officer finalized effective September 30, 2026, due to personal reasons.
- Board meeting commenced at 10:30 a.m. and concluded at 11:45 a.m. on September 30, 2026.
Sai Parenterals Limited announced the outcome and voting results of its 25th Annual General Meeting held on September 10, 2026. All 12 resolutions were approved by shareholders with requisite majority, including the adoption of FY26 financial statements and director re-appointments. Crucially, shareholders approved a variation in the objects/terms and an extension of the time period for utilizing IPO proceeds designated for capacity expansion, manufacturing upgrades, and an R&D centre. Additionally, material related-party transactions involving downstream loans and contracts with Australian step-down subsidiary Noumed Pharmaceuticals Pty Ltd were approved.
- All 12 resolutions approved with requisite majority at the 25th AGM held on September 10, 2026
- Approval granted for variation and timeline extension of IPO proceeds utilization for manufacturing upgrades and R&D
- Material related-party transactions approved for loans and operations with step-down subsidiary Noumed Pharmaceuticals Pty. Ltd (Australia)
- A total of 54 members attended the meeting conducted through Video Conferencing
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its OTC supply contract with a leading Australian pharmacy network for a 3-year term valued at AUD 30 million (~₹204 crore). This adds approximately AUD 10 million (~₹68 crore) in recurring annual revenue and expands the group's total contracted Australian OTC supply book to AUD 232 million (~₹1,506 crore). While current supplies are sourced from third-party manufacturers earning distribution margins, the company plans to transition production to its Adelaide and Indian facilities to capture higher manufacturing margins.
- 3-year OTC supply contract renewed at AUD 30 million (approximately ₹204 crore)
- Translates to an annual contracted run-rate of ~AUD 10 million (~₹68 crore)
- Cumulative contracted OTC book in Australia reaches AUD 232 million (~₹1,506 crore)
- Plan to shift production in-house upon commissioning of Adelaide plant to boost margins
Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed its OTC medicines supply agreement with a leading Australian pharmacy network. The contract spans a 3-year term starting August 24, 2026, with a projected value of AUD 30 million (~₹204 crore at ₹68.52/AUD). The renewed agreement brings an expanded product portfolio and a higher overall contract value compared to previous terms.
- Subsidiary Noumed Pharmaceuticals renewed 3-year supply agreement effective August 24, 2026
- Total projected contract value is AUD 30 million (approximately ₹204 crore)
- Conversion exchange rate applied is ₹68.52 per AUD
- Contract includes an expanded OTC medicines product portfolio with an international pharmacy chain
Sai Parenterals Limited has announced that its management will participate in an in-person group analyst and institutional investor meeting in Mumbai on August 31, 2026, starting at 10:00 AM. The interaction is hosted by Strategic Growth Advisors Pvt. Ltd. The company confirmed that discussions will rely strictly on publicly available information without disclosing any unpublished price sensitive information (UPSI).
- In-person group meeting scheduled for Monday, 31st August, 2026, at 10:00 AM onwards in Mumbai
- Interaction hosted by Strategic Growth Advisors Pvt. Ltd.
- Discussions to remain limited to publicly available information without sharing UPSI
Sai Parenterals Limited has announced its 25th Annual General Meeting (AGM) scheduled for September 10, 2026, at 11:00 AM IST via Video Conference. The company has fixed Thursday, September 3, 2026, as the record date/cut-off date for determining shareholder voting eligibility. Additionally, the Register of Members and share transfer books will remain closed from September 4, 2026, to September 10, 2026 (both days inclusive).
- 25th Annual General Meeting to be held on September 10, 2026, at 11:00 AM IST via VC/OAVM
- Cut-off/Record date for electronic voting set as September 3, 2026
- Book closure scheduled from September 4, 2026, to September 10, 2026 (both days inclusive)
Sai Parenterals has issued the notice for its 25th Annual General Meeting scheduled for September 10, 2026, along with its FY 2025-26 Annual Report. The report notes that FY26 consolidated revenue stood at ₹381 Crore, with Q4 FY26 contributing ₹198 Crore. The company operates 5 facilities with ~1,160 million units of annual installed capacity and highlighted the renewal of a ₹1,300 Crore Australian OTC supply agreement.
- 25th Annual General Meeting scheduled for September 10, 2026, via Video Conferencing
- Consolidated revenue for FY 2025-26 reached ₹381 Crore, supported by ₹198 Crore in Q4
- Annual manufacturing capacity stands at approximately 1,160 million units across 5 facilities
- Highlights renewal of a ₹1,300 Crore OTC medicines supply agreement in Australia via subsidiary Noumed
Sai Parenterals reported Q1 FY27 consolidated revenue of Rs. 182 crores, EBITDA of Rs. 27 crores (14.9% margin), and PAT of Rs. 8 crores, tracking toward full-year guidance of Rs. 750 crores at ~17% EBITDA margin. The Board approved redeploying Rs. 101.85 crores of IPO proceeds to acquire 60% stakes in Saicriti Pharma (Rs. 83.83 crores) and Prathyak Laboratories (Rs. 15 crores). The shift was driven by Hyderabad Industrial Lands Transformation Policy constraints at its existing sites. The Saicriti investment delivers 154.66 million units of injectable capacity (a 47% increase over original plan) targeting completion by April 2027, while the AUD 53 million Australia capex program remains on track.
- Q1 FY27 consolidated revenue stood at Rs. 182 crores with EBITDA of Rs. 27 crores (14.9% margin) and PAT of Rs. 8 crores.
- Reaffirmed FY27 revenue target of Rs. 750 crores with an expected EBITDA margin of approximately 17%.
- Redeploying Rs. 101.85 crores of IPO funds toward 60% stakes in Saicriti Pharma (Rs. 83.83 crores) and Prathyak Labs (Rs. 15 crores).
- Saicriti project delivers 154.66 million units of injectable capacity (+47% vs earlier plan) targeted for completion by April 2027.
- Australia AUD 53 million manufacturing facility is fully funded, targeting TGA licensing inspection by March 31, 2027.
Sai Parenterals has published the audio recording of its earnings conference call held on August 12, 2026, for the quarter ended June 30, 2026. This filing is a standard regulatory requirement under SEBI Listing Regulations. The recording provides management's perspective on the company's performance following a quarter (Mar 2026) where revenue reached Rs 198.0 cr with a PAT of Rs 13.0 cr. Investors can access the recording via the company's website to evaluate future growth guidance.
- Earnings call conducted on August 12, 2026, for the Q1 period ended June 30, 2026
- Audio recording made available via a public URL as per Regulation 30 of SEBI Listing Regulations
- Company reported a significant revenue jump to Rs 198.0 cr in Mar 2026 from Rs 96.0 cr in Dec 2025
- Net profit stood at Rs 13.0 cr for the quarter ended March 2026
Sai Parenterals has detailed a major structural shift, with export revenue surging from 3% in FY23 to 63% in FY26, primarily driven by the acquisition of Noumed (Australia). The company is executing a ₹571 crore capex program, which is approximately 1.5x its FY26 consolidated revenue of ₹381 crore. Key growth is anchored by a 7.5-year AUD 202 million exclusive supply agreement in Australia and a USD 11 million contract in the Philippines. While revenue grew 58% in FY26, consolidated EBITDA margins compressed to 10.2% from 24.1% in FY25 due to the Noumed integration and acquisition costs.
- ₹571 crore total capex program underway, with ₹440 crore funded by the company through IPO proceeds and grants.
- AUD 202 million (approx. ₹1,100+ cr) 7.5-year exclusive supply agreement in Australia effective July 1, 2026.
- Export revenue share increased to 63% in FY26 from 3% in FY23, with Australia accounting for 76% of exports.
- Installed capacity to expand from 1,160 million units to 1,469 million units p.a. post-expansion program.
- CDMO segment now contributes 63% of net revenue, growing at a 355.6% CAGR between FY23 and FY26.
Sai Parenterals reported a consolidated revenue of ₹182.4 crore for Q1 FY27, achieving 24% of its ₹750 crore annual revenue target. The company is pivoting its IPO fund utilization, redeploying ₹101.85 crore to acquire 60% stakes in Saicriti Pharma (a ₹215 crore injectable facility) and Prathyak Laboratories (an established R&D center) instead of greenfield projects. This strategic shift increases planned injectable capacity by 47% to 154.66 million units with only a one-month delay in completion (April 2027). Management maintained its FY27 guidance of ₹750 crore revenue with an EBITDA margin of approximately 17%.
- Consolidated revenue reached ₹182.4 crore in Q1 FY27, representing 24% of the ₹750 crore full-year target.
- Redeploying ₹83.83 crore of IPO proceeds to acquire a 60% stake in Saicriti Pharma, which is building a ₹215 crore EU-GMP/USFDA compliant facility.
- Acquiring a 60% stake in Prathyak Laboratories for ₹18.02 crore, gaining an R&D team of 65 personnel and a pipeline of 150 SKUs.
- Injectable capacity target increased by 47% to 154.66 million units compared to the original 105 million units planned in the IPO.
- Standalone PAT grew 975.1% YoY to ₹8.9 crore, while consolidated EBITDA margin improved 50 bps QoQ to 14.9%.
Sai Parenterals approved significant alterations to its IPO proceeds utilization, redirecting ₹838.34 million (originally for Unit I & II upgrades) to acquire a 60% stake in Saicriti Pharma, which is setting up a ₹2,149.60 million sterile injectables plant. Additionally, ₹180.23 million earmarked for a new R&D center will be used to acquire a 60% stake in Prathyak Laboratories, an operational R&D platform with 124 product developments. The board also approved key leadership appointments, the resignation of Non-Executive Director Aruna Karusala and the Company Secretary, and the incorporation of a US step-down subsidiary.
- ₹838.34 million IPO funds redirected to acquire 60% equity in Saicriti Pharma's ₹2,149.60 million greenfield injectables plant in Hyderabad
- ₹180.23 million IPO funds repurposed to acquire a 60% stake in Prathyak Laboratories with 124 product pipeline
- Managing Director Anil Kumar Karusala and WTD Vijitha Gorrepati re-appointed for 3 years starting January 1, 2027
- Resignation of Non-Executive Director Aruna Karusala effective August 11, 2026, and CS Shivali Aggarwal on/before October 12, 2026
- Approved incorporation of a new step-down subsidiary in the US via Singapore arm and material RPT loan to Noumed Pharmaceuticals Pty Ltd
Sai Parenterals has confirmed zero deviation in the utilization of its ₹285 crore IPO proceeds for the quarter ended June 30, 2026. The company has fully deployed funds allocated for working capital (₹33 crore) and the repayment of bridge loans used for its Australian acquisition (₹35.64 crore). However, utilization for the primary growth driver—capacity expansion—remains at an early stage, with only ₹6.81 crore spent out of the ₹110.79 crore allocated. No funds have been utilized yet for the proposed ₹18.02 crore R&D center.
- Total IPO proceeds of ₹2,850 million raised in March 2026 show zero deviation from stated objects.
- Capacity expansion and facility upgradation has seen only ₹68.10 million utilization against an allocation of ₹1,107.95 million.
- Fully utilized ₹356.41 million for repayment of bridge/term loans related to the acquisition of Noumed Pharmaceuticals (Australia).
- Working capital requirements of ₹330.00 million have been fully met using the issue proceeds.
- Zero utilization reported for the establishment of a new R&D Centre, which has an allocation of ₹180.23 million.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
